OncoMatch/Clinical Trials/NCT07485855

Influenza Vaccination Strategy for Patients With Hematologic Malignancy

Is NCT07485855 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including High-dose trivalent inactivated influenza vaccine (HD-IIV3) and MF59-adjuvanted quadrivalent inactivated influenza vaccine (aIIV4) for hematologic neoplasms.

Treatment: High-dose trivalent inactivated influenza vaccine (HD-IIV3) · MF59-adjuvanted quadrivalent inactivated influenza vaccine (aIIV4) · Standard-dose trivalent inactivated influenza vaccine (SD-IIV3) — This randomized controlled trial evaluates and compares the immunogenicity of three different influenza vaccine formulations: high-dose trivalent (HD-IIV3), MF59-adjuvanted quadrivalent (aIIV4), and standard-dose trivalent (SD-IIV3) vaccines. The study population consists of patients with hematologic malignancies, including those undergoing autologous stem cell transplantation or CAR-T cell therapy. The primary goal is to identify which vaccine strategy elicits the most robust antibody and T cell-mediated immune responses in this severely immunocompromised population